Savara price target raised to $8 from $6 at Oppenheimer

Oppenheimer raised the firm’s price target on Savara (SVRA) to $8 from $6 and keeps an Outperform rating on the shares following updated analysis pointing to 5,500 aPAP patients in the U.S. from previous estimates of 3,600 in 2023. This refreshed analysis of claims data giveline of sight to at least 1,000 patients by launch with 750 patients already identified. With no approved therapies in the U.S. to treat aPAP, these claims data reinforce the unmet need ahead of MOLBREEVI BLA submission in December, the firm says. With the analytical package being finalized and the recent NEJM publication underscoring the MOLBREEVI’s ability to address the underlying pathophysiology of aPAP, Oppenheimer is increasingly confident in a potential August 2026 approval, if granted Priority Review.